A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant"

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 5, 2009, Pages 509-513

  van Oort, I M ^a   Kok, Dieuwertje E G ^a,b   Kiemeney, Lambertus A ^a   Hulsbergen van de Kaa, Christina A ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Insignificant prostate cancer; Prognosis; Prostate; Prostatectomy; Small volume tumor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 69249093478     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.04.014     Document Type: Article

References (26)

1. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
2. Stamey T.A., Freiha F.S., McNeal J.E., et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (1993) 933-938
3. Jeldres C., Suardi N., Walz J., et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol (2007) in press; [doi:10.1016/j.eururo. 2007.11.057]
4. Allan R.W., Sanderson H., and Epstein J.I. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: Role of prostate specific antigen density. J Urol 170 (2003) 370-372
5. Chan T.Y., Chan D.Y., Stutzman K.L., et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 166 (2001) 2181-2184
6. Epstein J.I., Carmichael M., Partin A.W., et al. Is tumor volume an independent predictor of progression following radical prostatectomy?. A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 149 (1993) 1478-1481
7. Ruijter E.T., Miller G.J., Aalders T.W., et al. Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol 183 (1997) 369-375
8. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York (NY)
9. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
10. Renshaw A.A., Richie J.P., Loughlin K.R., et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 83 (1998) 748-752
11. Stamey T.A., McNeal J.E., Yemoto C.M., et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 281 (1999) 1395-1400
12. Wise A.M., Stamey T.A., McNeal J.E., et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60 (2002) 264-269
13. Nelson B.A., Shappell S.B., Chang S.S., et al. Tumor volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 97 (2006) 1169-1172
14. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
15. Singh H., Canto E.I., Shariat S.F., et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171 (2004) 1089-1092
16. Roemeling S., Roobol M.J., Kattan M.W., et al. Nomogram use for the prediction of indolent prostate cancer: Impact on screen-detected populations. Cancer 110 (2007) 2218-2221
17. Augustin H., Hammerer P.G., Graefen M., et al. Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 43 (2003) 455-460
18. Soh S., Kattan M.W., Berkman S., et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?. J Urol 157 (1997) 2212-2218
19. Noguchi M., Stamey T.A., McNeal J.E., et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166 (2001) 104-109
20. Stamey T.A., Donaldson A.N., Yemoto C.E., et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 160 (1998) 2412-2417
21. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
22. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
23. Cheng L., Jones T.D., Pan C.X., et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18 (2005) 1022-1026
24. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
25. Dvorak T., Chen M.H., Renshaw A.A., et al. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 66 (2005) 1024-1028
26. Bastian P.J., Mangold L.A., Epstein J.I., et al. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101 (2004) 2001-2005